bullish

Consun Pharmaceutical (1681.HK) - Undervalued. Good Performance Growth Will Continue

325 Views23 May 2023 08:55
The most intuitive information in 2022 report is that both revenue and profit of Consun had good growth, with stable dividend payout. Consun is undervalued and is expected to usher in valuation repair
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
  • Unlock all research summaries
  • Follow top, independent analysts
  • Receive personalised alerts and emails
  • Access Briefings, Analytics, and Events

Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.

Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
chart-bar
x